429 / 1498
CONCLUSIONS
•
There was no significant difference in RR, FFS, OS and 5-year
toxicity when ABVD (+RT for BMD) is compared with Stanford
V (+ RT for nodal sites >5 cm and macroscopic splenic disease)
•
Overall toxicity between the 2 arms was similar, but more
lymphopenia and neuropathy was seen in Stanford V
•
ABVD remains the standard of care
•
Patients with locally extensive disease do better than patients
with advanced disease
•
For patients with 3-7 IPS risk factors, there is a trend favoring
ABVD as measured by FFS